Previous reports have demonstrated the clinical practice of molecular characterization of CTCs through immunomagnetic separation or other methods to investigate the expression of IGFR132, mammaglobins33, or urinary plasminogen activator34 in breast cancer patients and of ERG, the androgen receptor, and PTEN6035 in prostate cancer patients. This evidence concerns the gene ERG and prostate carcinoma.